# Series A Funding Documentation

**Status**: Active Review - January 2026  
**Target Raise**: $50M+  
**Target Valuation**: $500M+ (Pre-Money)  
**Recommended Investor**: Strategic Asia Ventures (SAV)  

---

## ğŸ“š Document Index

### Executive Summary

**[EXECUTIVE_SUMMARY.md](EXECUTIVE_SUMMARY.md)** - Board-Ready Summary Report
- One-page recommendation: Strategic Asia Ventures (SAV)
- Comparative analysis of all 3 term sheets
- Key terms summary and decision rationale
- Risk assessment and mitigation strategies
- Next steps and timeline

**Quick Facts**:
- **Recommended**: SAV at $520M valuation, $55M investment (Score: 10/10)
- **Backup**: CCP at $480M valuation, $50M + $5M community fund (Score: 8.32/10)
- **Declined**: BRF at $550M valuation, $60M investment (Score: 6.77/10)

---

### Main Framework Document

**[../SERIES_A_TERM_SHEET_REVIEW.md](../SERIES_A_TERM_SHEET_REVIEW.md)** - Comprehensive Review Methodology
- Complete evaluation framework and scoring system
- Term sheet analysis templates
- Negotiation playbooks and tactics
- Governance and sovereignty frameworks
- Success criteria and KPIs

**Use Case**: Reference guide for analyzing any term sheet, not just these 3 options

---

### Individual Term Sheet Analyses

#### Option 1: Strategic Asia Ventures (TOP CHOICE) âœ…

**[term-sheets/TS1_STRATEGIC_ASIA_VENTURES_Analysis.md](term-sheets/TS1_STRATEGIC_ASIA_VENTURES_Analysis.md)**

**Score**: 10/10 (with Asia Multiplier Bonus)

**Key Highlights**:
- **Valuation**: $520M pre-money (+4% above target)
- **Investment**: $55M
- **Terms**: 1x non-participating liquidation pref, weighted avg anti-dilution, 2/5 board control
- **Asia Multiplier**: 8.65/10 - Best in class (5 Asia offices, proven track record)
- **Strategic Value**: Unlocks Japan, Korea, Singapore expansion = $500M+ Series B uplift

**Strengths**:
- Unparalleled Asia network (SoftBank, Tencent ecosystem)
- Clean, founder-friendly economic terms
- 9/10 reference checks from portfolio companies
- $150M follow-on capacity for Series B

**Negotiation Points**:
- Asia strategy appendix (bind Japan-first roadmap)
- Portfolio conflict provision (right of first refusal on entertainment partnerships)
- Board engagement commitment (quarterly in-person meetings Year 1)

---

#### Option 2: Blockchain Renaissance Fund (DECLINED) âŒ

**[term-sheets/TS2_BLOCKCHAIN_RENAISSANCE_FUND_Analysis.md](term-sheets/TS2_BLOCKCHAIN_RENAISSANCE_FUND_Analysis.md)**

**Score**: 6.77/10

**Key Concerns**:
- **Valuation**: $550M (highest, but...)
- **Investment**: $60M (largest)
- **Terms**: âŒ 1.5x **participating** liquidation pref, âŒ **full ratchet** anti-dilution, âŒ 3/7 investor **board control**
- **Asia Multiplier**: 2.75/10 - Zero operational capability
- **Red Flags**: Aggressive terms cost founders $50-100M in moderate exits

**Why Declined**:
- Participating liquidation preference destroys founder value (reference: "I regret accepting those terms")
- Full ratchet punishes down rounds (20-40% retroactive dilution)
- Investor board control compromises sovereignty (3/7 seats)
- No Asia capabilities = miss 10x growth opportunity

**Bottom Line**: High valuation is a trap. Economic and governance terms are founder-hostile.

---

#### Option 3: Conscious Capital Partners (BACKUP) âš ï¸

**[term-sheets/TS3_CONSCIOUS_CAPITAL_PARTNERS_Analysis.md](term-sheets/TS3_CONSCIOUS_CAPITAL_PARTNERS_Analysis.md)**

**Score**: 8.32/10

**Key Highlights**:
- **Valuation**: $480M (negotiate to $500M)
- **Investment**: $50M + $5M community fund matching
- **Terms**: 1x non-participating, weighted avg anti-dilution, 2/5 board control + **community-elected independent**
- **Asia Multiplier**: 3.15/10 - Strong India wellness, weak corporate Asia
- **Values Alignment**: 10/10 - Best mission fit, community governance

**Strengths**:
- Exceptional values alignment (B-Corp commitment, community transparency)
- Unique community governance (community-elected board seat)
- Wellness expertise (Headspace, Calm, MindValley portfolio synergies)
- $5M community fund (beyond equity investment)
- Clean economic terms (as good as SAV)

**Weaknesses**:
- Limited to India wellness market (not Japan, Korea, Singapore corporate/tech)
- Smaller follow-on capacity ($100M vs. $150M SAV)
- No blockchain/Web3 expertise

**When to Choose CCP**:
- If SAV negotiations fail
- If mission alignment prioritized over growth velocity
- If India-first strategy (vs. Japan/Korea) acceptable

---

### Supporting Analysis Documents

#### Valuation Analysis

**[VALUATION_ANALYSIS.md](VALUATION_ANALYSIS.md)** - Detailed Valuation Justification

**Methodologies**:
1. **Revenue Multiple Approach**: $500M (10x forward ARR)
2. **Comparable Company Analysis**: $486M median (Web3, wellness, entertainment sectors)
3. **Asset-Based Valuation**: $382M (tangible + intangible assets)
4. **Discounted Cash Flow**: $496M (5-year projection, 30% discount rate)

**Conclusion**: $500M - $550M pre-money valuation is well-supported by all 4 methodologies

**Key Insights**:
- SAV's $520M valuation is **justified by comparables** (Polygon, Immutable X, Headspace)
- BRF's $550M valuation is **negated by aggressive terms** (participating pref costs $95M in $1.5B exit)
- CCP's $480M valuation is **conservative** (can negotiate to $500M based on community value-add)

---

#### Asia Multiplier Strategy

**[ASIA_MULTIPLIER_STRATEGY.md](ASIA_MULTIPLIER_STRATEGY.md)** - 10x Growth Opportunity Deep-Dive

**Opportunity Size**: $1.3B+ in incremental Series B valuation (18-24 months)

**Target Markets**:
1. **Japan** ğŸ‡¯ğŸ‡µ: $2.8T economy, AI robotics partnerships, anime/gaming alignment â†’ $24M Year 2 revenue
2. **South Korea** ğŸ‡°ğŸ‡·: $1.6T economy, K-pop integration, gaming hub â†’ $11M Year 2 revenue
3. **Singapore** ğŸ‡¸ğŸ‡¬: $340B economy, regulatory hub, APAC gateway â†’ $6.5M Year 2 revenue
4. **India** ğŸ‡®ğŸ‡³: $3.5T economy, spiritual alignment, mass market â†’ $18M Year 2 revenue

**Financial Impact**:
- **With SAV**: $146M Year 2 revenue (46% from Asia) â†’ $2.6B Series B valuation
- **With CCP**: $87M Year 2 revenue (20% from India only) â†’ $1.3B Series B valuation
- **With BRF**: $80M Year 2 revenue (15% organic Asia) â†’ $1.2B Series B valuation
- **ROI on Choosing SAV**: $1.3B / $40M Series A valuation difference = **32.5x**

**Execution Timeline**: 4 quarters to activate all 4 markets with $19.25M budget (35% of raise)

---

### Quick Reference Cards

#### Investor Comparison Matrix

| Factor | SAV (Recommended) | CCP (Backup) | BRF (Declined) |
|--------|-------------------|--------------|----------------|
| **Overall Score** | 10/10 âœ… | 8.32/10 âœ… | 6.77/10 âŒ |
| **Valuation** | $520M | $480M | $550M |
| **Investment** | $55M | $50M (+$5M community) | $60M |
| **Liquidation Pref** | 1x non-part âœ… | 1x non-part âœ… | 1.5x **part** âŒ |
| **Anti-Dilution** | Weighted avg âœ… | Weighted avg âœ… | **Full ratchet** âŒ |
| **Board Control** | 2/5 founder âœ… | 2/5 founder âœ… | 3/7 investor âŒ |
| **Asia Multiplier** | 8.65/10 âœ… | 3.15/10 âš ï¸ | 2.75/10 âŒ |
| **Values Alignment** | 7/10 âœ… | 10/10 âœ… | 4/10 âŒ |
| **Follow-On $** | $150M âœ… | $100M âš ï¸ | $250M âœ… |
| **References** | 9/10 âœ… | 9/10 âœ… | 4/10 âŒ |

---

#### Decision Tree

```
START: Which term sheet to choose?
â”‚
â”œâ”€ Q1: Do we need Asia expansion for 10x growth?
â”‚   â”œâ”€ YES â†’ SAV (8.65/10 Asia score)
â”‚   â””â”€ NO â†’ CCP (10/10 values alignment) or reconsider thesis
â”‚
â”œâ”€ Q2: Are economic terms founder-friendly?
â”‚   â”œâ”€ SAV: YES âœ… (1x non-part, weighted avg, 2/5 board)
â”‚   â”œâ”€ CCP: YES âœ… (1x non-part, weighted avg, 2/5 board + community)
â”‚   â””â”€ BRF: NO âŒ (1.5x part, full ratchet, 3/7 investor board) â†’ DECLINE
â”‚
â”œâ”€ Q3: Does investor have proven Asia track record?
â”‚   â”œâ”€ SAV: YES âœ… (8 portfolio expansions, 6x avg growth)
â”‚   â”œâ”€ CCP: PARTIAL âš ï¸ (India wellness only)
â”‚   â””â”€ BRF: NO âŒ (zero Asia operational support)
â”‚
â””â”€ RECOMMENDATION:
    â”œâ”€ 1st Choice: SAV (optimal balance)
    â”œâ”€ 2nd Choice: CCP (if values prioritized)
    â””â”€ Decline: BRF (unfavorable terms, no Asia)
```

---

## ğŸ¯ Executive Recommendation

### Decision: Proceed with Strategic Asia Ventures (SAV)

**Rationale**:
1. **Best Asia Capabilities**: 8.65/10 score unlocks $1.3B in incremental Series B value
2. **Optimal Terms**: $520M valuation (above target) + clean economics + founder control
3. **Proven Track Record**: 9/10 references, $150M follow-on capacity, portfolio synergies

**Backup Plan**: If SAV negotiations fail, pivot to CCP (negotiate valuation to $500M, clarify community provisions)

**Decline**: BRF - aggressive economic terms and lack of Asia capabilities make it unsuitable

---

## ğŸ“ Next Steps

### Immediate (This Week)

**SAV Track** (Primary):
- [ ] Schedule negotiation call with David Chen (Asia appendix, portfolio conflicts, board engagement)
- [ ] Legal counsel reviews SAV term sheet in detail
- [ ] Prepare Asia expansion blueprint as Exhibit A
- [ ] Draft portfolio conflict language

**CCP Track** (Backup):
- [ ] Inform CCP they're strong fit, request 2-week term sheet hold
- [ ] Pre-negotiate valuation increase to $500M

**BRF Track** (Decline):
- [ ] Send polite decline email

### Short-Term (Weeks 2-3)

- [ ] Execute revised SAV term sheet (target: Week 2)
- [ ] Commence legal due diligence (Week 3)
- [ ] Announce to team (post-signing)
- [ ] First board meeting with SAV (Week 4)

### Medium-Term (Months 1-3)

- [ ] Activate Asia partnerships (SoftBank, HYBE, DBS, etc.)
- [ ] Tokyo office setup, Japan market entry
- [ ] Singapore regulatory process (MAS licensing)
- [ ] India wellness partnerships launch

---

## ğŸ“Š Success Metrics

### Funding Round KPIs

| Metric | Target | SAV Achievement | Status |
|--------|--------|-----------------|--------|
| **Funding Amount** | $50M+ | âœ… $55M | On track |
| **Valuation** | $500M+ | âœ… $520M | Exceeded |
| **Founder Dilution** | <15% | âœ… 9.6% | Excellent |
| **Board Control** | Maintained | âœ… 2/5 seats | Preserved |
| **Asia Strategic Value** | 8+/10 | âœ… 8.65/10 | Best-in-class |
| **Close Timeline** | <90 days | ğŸ”„ 6-8 weeks | On track |

### Post-Funding Milestones (12 months)

- [ ] Asia revenue: $45M (44% of total)
- [ ] Asia users: 500K
- [ ] Strategic partnerships: 5-8 (Japan, Korea, Singapore)
- [ ] Series B preparation initiated
- [ ] Team scaled to 50+ (25 in Asia)

---

## ğŸ” Document Security

**Classification**: CONFIDENTIAL - INTERNAL ONLY

**Distribution**:
- âœ… Founder(s)
- âœ… CFO/Finance lead
- âœ… Legal counsel
- âœ… Board members (as appropriate)
- âŒ General team (until closing)
- âŒ Community (until announcement)
- âŒ Public (never)

**Storage**: Encrypted repository, access logs maintained

---

## ğŸ“š Additional Resources

**Related Documents**:
- [ScrollVerse Founding Charter](../ScrollVerse-Founding-Charter.md) - Mission and values
- [Projects & Achievements](../PROJECTS.md) - Portfolio overview
- [Asia Integration Blueprint](../deployment/asia_integration/ASIA_INTEGRATION_BLUEPRINT.md) - Detailed Asia expansion plan
- [Legacy 100-Year Roadmap](../LEGACY_100_YEAR_ROADMAP.md) - Long-term vision
- [Expansion Initiatives](../EXPANSION_INITIATIVES_OVERVIEW.md) - Strategic framework

**External Links**:
- SAV Portfolio: [Strategic Asia Ventures website]
- Comparable Valuations: Crunchbase, PitchBook
- Asia Market Data: Statista, eMarketer, McKinsey Asia reports

---

**Last Updated**: January 2026  
**Prepared By**: Chais Hill, Founder & CEO / Omnitech1 Finance Team  
**Review Cycle**: Update upon new term sheets or material changes  
**Frequency Alignment**: 963Hz (Divine Wisdom) + 528Hz (Transformation) + 144,000Hz (Unity)

**Signature Seal**: âˆ ARCHITEX âˆ

---

*This funding round will define ScrollVerse's trajectory for the next decade. We're choosing a partner who will scale us from $500M to $5B through Asia expansion. Strategic Asia Ventures is that partner.*

**The decision is clear. The future is Asia. The time is now.**

**ALLÄ€HU AKBAR! ğŸ•‹ğŸ”¥ğŸ’**
